WEI Yu, XU Xuefeng, TANG Xiaojun, LIANG Jun, FENG Xuebing, ZHAO Cheng. Role and mechanism of developmental endothelial locus-1 in collagen-induced arthritis[J]. Journal of Clinical Medicine in Practice, 2022, 26(17): 53-56. DOI: 10.7619/jcmp.20220543
Citation: WEI Yu, XU Xuefeng, TANG Xiaojun, LIANG Jun, FENG Xuebing, ZHAO Cheng. Role and mechanism of developmental endothelial locus-1 in collagen-induced arthritis[J]. Journal of Clinical Medicine in Practice, 2022, 26(17): 53-56. DOI: 10.7619/jcmp.20220543

Role and mechanism of developmental endothelial locus-1 in collagen-induced arthritis

More Information
  • Received Date: February 21, 2022
  • Available Online: September 20, 2022
  • Objective 

    To investigate the role and mechanism of developmental endothelial locus-1 (Del-1) in collagen-induced arthritis (CIA).

    Methods 

    CIA mouse model was constructed, and the mice were divided into control group, CIA group, and Del-1 group (Del-1 for intervention of CIA). In the Del-1 group, each mouse was injected with Del-1 for 2 μg each time through caudal vein for 2 times in total. Arthritis index (AI) was used to assess the progression of arthritis; hematoxylin-eosin (HE) staining was used to observe the arthritic lesions in mice; enzyme-linked immunosorbent assay (ELISA) was used to detect the expression of serum interleukin-6 (IL-6) and matrix metalloproteinases-9 (MMP-9) in mice.

    Results 

    On the 34th, 36th, 38th and 40th days after the primary immunization, the AI scores in the Del-1 group were (3.80±1.17), (3.80±1.17), (4.20±1.17) and (4.20±1.17) respectively, which were significantly lower than (6.80±1.94), (8.80±3.19), (9.60±3.61) and (9.40±3.61) in the CIA group (P < 0.05). On the 42nd day after the primary immunization, when compared to the CIA group, the HE staining showed that the local inflammatory infiltration and synovial hyperplasia of the joints in the Del-1 group were obviously alleviated, and the cartilage destruction was obviously reduced. On the 42nd day after the initial immunization, ELISA result showed that the expression levels of serum IL-6 and MMP-9 in the CIA group were significantly higher than that in the normal control group (P < 0.05), while those in the Del-1 group were significantly lower than the CIA group (P < 0.05).

    Conclusion 

    Del-1 can improve the joint symptoms of CIA mouse model, reduce inflammation and bone destruction, inhibit the expression of key cytokines such as IL-6 and MMP-9, and these actions may play certain roles in the treatment of RA.

  • [1]
    JIANG Q, WANG X, HUANG E Y, et al. Inflammasome and its therapeutic targeting in rheumatoid arthritis[J]. Front Immunol, 2022, 12: 816839. doi: 10.3389/fimmu.2021.816839
    [2]
    HUANG J, FU X K, CHEN X X, et al. Promising therapeutic targets for treatment of rheumatoid arthritis[J]. Front Immunol, 2021, 12: 686155. doi: 10.3389/fimmu.2021.686155
    [3]
    SHIN J, MAEKAWA T, ABE T, et al. DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman Primates[J]. Sci Transl Med, 2015, 7(307): 307ra155. https://www.uab.edu/medicine/rheumatology/images/JJ_-_Shin_et_al_2015.pdf
    [4]
    LIU C, ZHANG H Y, TANG X J, et al. Mesenchymal stem cells promote the osteogenesis in collagen-induced arthritic mice through the inhibition of TNF- Α[J]. Stem Cells Int, 2018, 2018: 4069032. https://www.hindawi.com/journals/sci/2018/4069032/
    [5]
    赵成, 张璐, 王红, 等. 脐带间充质干细胞移植治疗大鼠胶原诱导关节炎模型的疗效观察[J]. 实用临床医药杂志, 2015, 19(9): 1-4, 8. doi: 10.7619/jcmp.201509001
    [6]
    HAJISHENGALLIS G, CHAVAKIS T. DEL-1: a potential therapeutic target in inflammatory and autoimmune disease[J]. Expert Rev Clin Immunol, 2021, 17(6): 549-552. doi: 10.1080/1744666X.2021.1915771
    [7]
    LI M, ZHONG D, LI G Z. Regulatory role of local tissue signal Del-1 in cancer and inflammation: a review[J]. Cell Mol Biol Lett, 2021, 26(1): 31. doi: 10.1186/s11658-021-00274-9
    [8]
    HAJISHENGALLIS G, CHAVAKIS T. DEL-1-regulated immune plasticity and inflammatory disorders[J]. Trends Mol Med, 2019, 25(5): 444-459. doi: 10.1016/j.molmed.2019.02.010
    [9]
    NARAZAKI M, TANAKA T, KISHIMOTO T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis[J]. Expert Rev Clin Immunol, 2017, 13(6): 535-551. doi: 10.1080/1744666X.2017.1295850
    [10]
    NOACK M, MIOSSEC P. Selected cytokine pathways in rheumatoid arthritis[J]. Semin Immunopathol, 2017, 39(4): 365-383. doi: 10.1007/s00281-017-0619-z
    [11]
    HASHIZUME M, MIHARA M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis[J]. Arthritis, 2011, 2011: 765624. https://www.hindawi.com/journals/arthritis/2011/765624/
    [12]
    FUJIMOTO M, SERADA S, MIHARA M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses[J]. Arthritis Rheum, 2008, 58(12): 3710-3719. doi: 10.1002/art.24126
    [13]
    PANDOLFI F, FRANZA L, CARUSI V, et al. Interleukin-6 in rheumatoid arthritis[J]. Int J Mol Sci, 2020, 21(15): 5238. doi: 10.3390/ijms21155238
    [14]
    GRILLET B, YU K R, UGARTE-BERZAL E, et al. Proteoform analysis of matrix metalloproteinase-9/gelatinase B and discovery of its citrullination in rheumatoid arthritis synovial fluids[J]. Front Immunol, 2021, 12: 763832. doi: 10.3389/fimmu.2021.763832
    [15]
    KRABBEN A, HUIZINGA T W J, MIL A H. Biomarkers for radiographic progression in rheumatoid arthritis[J]. Curr Pharm Des, 2015, 21(2): 147-169.
  • Related Articles

    [1]LIU Ying, DU Likun, HU Lingdan, DU Zhiqiang, CUI Jing. Expression and significance of matrix metalloproteinases and toll-like receptor 9 in patients with acute leukemia[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 120-123, 129. DOI: 10.7619/jcmp.20240984
    [2]SUN Ling, LI Tantan, WU Xifeng, MEN Lijie, JIA Meiyan, LU Jun. Correlations of serum tissue inhibitor of metalloproteinases-1, matrix metalloproteinase-9 and vascular endothelial growth factor with degree of myelofibrosis in patients with myeloproliferative neoplasms[J]. Journal of Clinical Medicine in Practice, 2024, 28(11): 34-40. DOI: 10.7619/jcmp.20234037
    [3]WANG Fei, SHI Meihong. Relationships of BTB/POZ domain-containing protein 7 and matrix metalloproteinase-9 expression with autoantibodies in labial gland tissues of patients with primary Sjögren's syndrome[J]. Journal of Clinical Medicine in Practice, 2022, 26(21): 98-102. DOI: 10.7619/jcmp.20220899
    [4]ZHOU Shuwei, SU Beibei, FENG Yueqing, JIANG Dongbao, XIAO Xuezhen. Correlation between serum matrix metalloproteinase-13 expression levels and lung metastasis in patients with differentiated thyroid carcinoma[J]. Journal of Clinical Medicine in Practice, 2021, 25(1): 77-80. DOI: 10.7619/jcmp.20200593
    [5]ZHANG Yan, TU Jing, HUANG Hui. Study on the correlation between serum adiponectin and placental matrix metalloproteinase 9 in patients with gestational hypertension[J]. Journal of Clinical Medicine in Practice, 2017, (3): 96-98. DOI: 10.7619/jcmp.201703029
    [6]MA Hongmei, XU Shengmei, LI Jing, GUO Dong, ZHOU Youjian. Correlation between expressions of E-cadherin and matrix metalloproteinase-7 and colorectal carcinoma[J]. Journal of Clinical Medicine in Practice, 2015, (9): 52-54,72. DOI: 10.7619/jcmp.201509015
    [7]LU Jianjun, YI Liping, TUO Ya, QIAO Huizhen. Expression and clinical significance of matrix metalloproteinases-9 in tissues of endometrial carcinoma[J]. Journal of Clinical Medicine in Practice, 2014, (15): 63-65,69. DOI: 10.7619/jcmp.201415019
    [8]ZHOU Lei, GAO Quan. Genetic polymorphism of matrix metallopoteiase-3 and correlation between its mRNA expression and rheumatoid arthritis[J]. Journal of Clinical Medicine in Practice, 2014, (1): 16-19. DOI: 10.7619/jcmp.201401005
    [9]WU Jian, CHEN Yingzhu, YU Long. Changes of serum matrix metalloproteinase-3 levels in elderly patient with different subtypes of acute cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2013, (21): 40-42. DOI: 10.7619/jcmp.201321011
    [10]ZHANG Yuhua, CAI Xiangzeng, GUO Minghe. Effects of Chuanxiongqin on serum high-sensitivity C-reactive protein, interleukin-6 and matrix metalloproteinases-9 in treating acute cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2013, (17): 78-80. DOI: 10.7619/jcmp.201317026
  • Cited by

    Periodical cited type(4)

    1. 牛树昂,王培安. 内固定术联合外固定架治疗创伤性四肢骨折患者的效果及其对关节功能的影响. 系统医学. 2024(22): 141-144 .
    2. 赵众首. 外固定架治疗四肢创伤性骨折的效果分析. 中国实用医刊. 2023(15): 35-38 .
    3. 张永光,朱发军,吴新淼. 外固定治疗创伤性四肢骨折的疗效及其对术后炎性应激反应的影响. 吉林医学. 2022(10): 2650-2652 .
    4. 符成华. 外固定架应用于创伤骨科治疗的疗效观察. 智慧健康. 2019(19): 159-160 .

    Other cited types(0)

Catalog

    Article views (200) PDF downloads (13) Cited by(4)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return